HLN
Haleon plcExplain this page
Arphra AIPlain-English read on Haleon plc’s valuationCompany profile
DB · companies + sec_company_profile + company_profilesHaleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Identifiers
- SymbolHLN
- Legal nameHaleon plc
- CEOBrian James McNamara
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CountryGB
- CurrencyUSD
- ExchangeNYSE
- IPO dateJul 25, 2022
- CIK0001900304
- ISINUS4055521003
- CUSIP405552100
- LEI—
- Employees24,561
Trading
DB · key_metrics_ttm- Market cap$38.61B
- P/E (TTM)—
- P/B—
- EV / EBITDA—
- Dividend yield—
Identifiers
OpenFIGI · GLEIFCross-source keys used to bridge market-data, SEC, and non-US sources.
- FIGIBBG018GZNCH6
- CountryGB